Abstract
OBJECTIVE: To review the role of Rho GTPase Activating Protein (ARHGAP) and Bone Marrow Kinase X (BMX) in the progression and development of gastric cancer (GC), and to highlight their potential as therapeutic targets. METHOD: A comprehensive literature review was conducted to assess current evidence regarding the involvement of ARHGAP and BMX in GC, focusing on their expression levels, association with prognosis, and impact on tumor behavior. RESULTS: Current research indicates that both ARHGAP and BMX are up-regulated in GC tissues, correlating with poor prognosis and aggressive tumor characteristics. These findings suggest that they play significant roles in the mechanisms underlying GC progression. CONCLUSION: The evidence supports the critical involvement of ARHGAP and BMX in GC, suggesting their potential as therapeutic targets. Further research is essential to clarify the mechanisms by which these proteins influence gastric cancer progression and to evaluate their viability as targets for new therapeutic strategies.